Tiziana Life Sciences Stock Price, News & Analysis (LON:TILS)

GBX 140 1.50 (1.08 %)
(As of 01/17/2018 03:11 PM ET)
Previous CloseGBX 140
Today's RangeGBX 137.06 - GBX 140
52-Week RangeGBX 102.06 - GBX 240
Volume136 shs
Average Volume3,835 shs
Market Capitalization£173.20 million
P/E Ratio-1,555.56
Dividend YieldN/A
BetaN/A

About Tiziana Life Sciences (LON:TILS)

Tiziana Life Sciences logoTiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.

Receive TILS News and Ratings via Email

Sign-up to receive the latest news and ratings for TILS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Investment Trusts
Sub-IndustryN/A
SectorInvestment Trusts
SymbolLON:TILS
CUSIPN/A
Phone+44-20-74952379

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-1555.55555555556
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.09)
Net IncomeN/A
Net MarginsN/A
Return on Equity-457.77%
Return on Assets-208.53%

Miscellaneous

EmployeesN/A
Outstanding Shares123,830,000

Tiziana Life Sciences (LON:TILS) Frequently Asked Questions

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) issued its quarterly earnings results on Friday, September, 29th. The biotechnology company reported ($4.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.00) by $2.10. View Tiziana Life Sciences' Earnings History.

Where is Tiziana Life Sciences' stock going? Where will Tiziana Life Sciences' stock price be in 2018?

1 brokerages have issued 12 month price targets for Tiziana Life Sciences' shares. Their forecasts range from GBX 400 to GBX 400. On average, they expect Tiziana Life Sciences' stock price to reach GBX 400 in the next year. View Analyst Ratings for Tiziana Life Sciences.

Who are some of Tiziana Life Sciences' key competitors?

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the folowing people:

  • Gabriele M. Cerrone, Executive Chairman of the Board (Age 42)
  • Kunwar Shailubhai Ph.D., Chief Executive Officer, Chief Scientific Officer, Director (Age 59)
  • Tiziano Lazzaretti, Chief Financial Officer
  • James Tripp, Chief Operating Officer, Head of Global Clinical Operations (Age 46)
  • P. Cooper, Company Secretary
  • Percy W. C. Lomax, Non-Executive Director
  • Willy Jules Simon, Non-Executive Director (Age 64)

How do I buy Tiziana Life Sciences stock?

Shares of Tiziana Life Sciences and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tiziana Life Sciences' stock price today?

One share of Tiziana Life Sciences stock can currently be purchased for approximately GBX 140.

How big of a company is Tiziana Life Sciences?

Tiziana Life Sciences has a market capitalization of £173.20 million.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.


MarketBeat Community Rating for Tiziana Life Sciences (TILS)

Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tiziana Life Sciences (LON:TILS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 400GBX 400GBX 0.20GBX 400

Tiziana Life Sciences (LON:TILS) Consensus Price Target History

Price Target History for Tiziana Life Sciences (LON:TILS)

Tiziana Life Sciences (LON:TILS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/19/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 400View Rating Details
(Data available from 1/17/2016 forward)

Earnings

Tiziana Life Sciences (LON:TILS) Earnings History and Estimates Chart

Earnings by Quarter for Tiziana Life Sciences (LON:TILS)

Tiziana Life Sciences (LON TILS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/29/2017S1 2017GBX (2)GBX (4.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tiziana Life Sciences (LON:TILS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Tiziana Life Sciences (LON:TILS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tiziana Life Sciences (LON TILS)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Tiziana Life Sciences (LON TILS) News Headlines

Source:
DateHeadline
Tiziana Life Sciences (TILS) Speculative Buy Rating Reaffirmed at Beaufort SecuritiesTiziana Life Sciences' (TILS) Speculative Buy Rating Reaffirmed at Beaufort Securities
www.americanbankingnews.com - December 24 at 5:02 PM
Tiziana Life Sciences Raise GBP200,000 For Clinical Trial Development (ALLISS)Tiziana Life Sciences Raise GBP200,000 For Clinical Trial Development (ALLISS)
www.morningstar.co.uk - December 15 at 11:26 AM
Tiziana Life Sciences Announces Safety of Milciclib in a Phase 2a Trial in Unresectable or Metastatic Hepatocellular Carcinoma (HCC) PatientsTiziana Life Sciences Announces Safety of Milciclib in a Phase 2a Trial in Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients
finance.yahoo.com - December 11 at 4:04 PM
Milciclib Phase 2a Trial Update - London South East (blog)Milciclib Phase 2a Trial Update - London South East (blog)
www.lse.co.uk - December 10 at 10:44 AM
Tiziana Life Sciences (TILS) Given Speculative Buy Rating at Beaufort SecuritiesTiziana Life Sciences (TILS) Given Speculative Buy Rating at Beaufort Securities
www.americanbankingnews.com - November 28 at 11:26 PM
Tiziana Life Sciences Raises GBP275,000 Via Share Issue (ALLISS)Tiziana Life Sciences Raises GBP275,000 Via Share Issue (ALLISS)
www.morningstar.co.uk - November 28 at 11:10 AM
Tiziana Life Sciences Plc (“Tiziana” or the “Company”): Placing to Raise £275,000Tiziana Life Sciences Plc (“Tiziana” or the “Company”): Placing to Raise £275,000
finance.yahoo.com - November 27 at 4:01 PM
Phase II Clinical Trial Update - London South East (blog)Phase II Clinical Trial Update - London South East (blog)
www.lse.co.uk - November 25 at 5:54 PM
Tiziana Life Sciences Raises GBP150,000 Via Share Issue (ALLISS)Tiziana Life Sciences Raises GBP150,000 Via Share Issue (ALLISS)
www.morningstar.co.uk - November 20 at 11:04 AM
How Does Investing In Tiziana Life Sciences PLC (AIM:TILS) Impact Your Portfolio?How Does Investing In Tiziana Life Sciences PLC (AIM:TILS) Impact Your Portfolio?
finance.yahoo.com - October 3 at 1:35 PM
Motif Bio Share ChatMotif Bio Share Chat
www.lse.co.uk - October 1 at 7:08 PM
2 small-cap growth stocks that could make you a millionaire2 small-cap growth stocks that could make you a millionaire
www.fool.co.uk - September 30 at 7:33 PM
Tiziana Life Sciences Interim Loss Widens In "Busy" First HalfTiziana Life Sciences Interim Loss Widens In "Busy" First Half
www.morningstar.co.uk - September 29 at 10:07 AM
Tiziana Life Sciences PLC (TILS) Releases Quarterly  Earnings Results, Misses Estimates By $2.10 EPSTiziana Life Sciences PLC (TILS) Releases Quarterly Earnings Results, Misses Estimates By $2.10 EPS
www.americanbankingnews.com - September 29 at 8:20 AM
Tiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort SecuritiesTiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - September 10 at 12:44 PM
A Proprietary Oral Formulation of Foralumab - London South East (registration) (blog)A Proprietary Oral Formulation of Foralumab - London South East (registration) (blog)
www.lse.co.uk - September 7 at 9:58 AM
Tiziana Life Sciences Develops Oral Formulation Of ForalumabTiziana Life Sciences Develops Oral Formulation Of Foralumab
www.morningstar.co.uk - September 6 at 9:10 AM
Beaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)Beaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)
www.americanbankingnews.com - August 20 at 5:02 PM
Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy ... - Business Wire (press release)Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy ... - Business Wire (press release)
www.businesswire.com - July 30 at 6:43 AM
Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune DiseasesPublication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
finance.yahoo.com - July 28 at 8:48 AM
Tiziana Life Sciences PLC (LON:TILS) Receives "Speculative Buy" Rating from Beaufort SecuritiesTiziana Life Sciences PLC (LON:TILS) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - July 23 at 10:48 AM
Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular CarcinomaTiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma
finance.yahoo.com - July 20 at 8:35 AM
Proposed changes to CLNs and Warrant Terms - London South East (registration) (blog)Proposed changes to CLNs and Warrant Terms - London South East (registration) (blog)
www.lse.co.uk - July 14 at 9:13 AM
Bcl-3 pre-clinical update and Directors dealing - London South East (registration) (blog)Bcl-3 pre-clinical update and Director's dealing - London South East (registration) (blog)
www.lse.co.uk - June 10 at 3:24 AM
Tiziana Life Sciences Stops Funding For Cardiff University Programme (ALLISS)Tiziana Life Sciences Stops Funding For Cardiff University Programme (ALLISS)
www.morningstar.co.uk - June 9 at 1:55 AM
Biotech Is Really Interested in 100-Year-Old ItaliansBiotech Is Really Interested in 100-Year-Old Italians
www.bloomberg.com - June 2 at 8:26 PM
Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with ... - Business Wire (press release)Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with ... - Business Wire (press release)
www.businesswire.com - April 26 at 3:17 PM
Warrant Expiry - Reminder - London South East (registration) (blog)Warrant Expiry - Reminder - London South East (registration) (blog)
www.lse.co.uk - January 18 at 12:30 AM
Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody - Business Wire (press release)Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody - Business Wire (press release)
www.businesswire.com - January 4 at 6:44 AM
Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal AntibodyTiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody
uk.finance.yahoo.com - January 3 at 9:18 AM
Half Year 2016 Tiziana Life Sciences PLC Earnings Release - Before Market OpenHalf Year 2016 Tiziana Life Sciences PLC Earnings Release - Before Market Open
biz.yahoo.com - September 29 at 10:19 AM
Tiziana Life Sciences PLC: Change of Registered OfficeTiziana Life Sciences PLC: Change of Registered Office
www.streetinsider.com - August 18 at 8:01 PM
Tiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of EquityTiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity
www.marketwatch.com - June 29 at 10:31 AM
Full Year 2015 Tiziana Life Sciences PLC Earnings Release - Time Not SuppliedFull Year 2015 Tiziana Life Sciences PLC Earnings Release - Time Not Supplied
biz.yahoo.com - June 7 at 7:07 AM
Tiziana reveals possible new anti-cancer moleculeTiziana reveals possible new anti-cancer molecule
uk.finance.yahoo.com - January 8 at 4:25 AM

SEC Filings

Tiziana Life Sciences (LON:TILS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Tiziana Life Sciences (LON TILS) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.